Literature DB >> 16215684

Mechanisms of induction of apoptosis by anthraquinone anticancer drugs aclarubicin and mitoxantrone in comparison with doxorubicin: relation to drug cytotoxicity and caspase-3 activation.

A Koceva-Chyła1, M Jedrzejczak, J Skierski, K Kania, Z Jóźwiak.   

Abstract

We examined molecular events and morphological features associated with apoptosis induced by anthraquinone anticancer drugs aclarubicin, mitoxantrone and doxorubicin in two spontaneously immortalized cell lines (NIH 3T3 and B14) in relation to cytotoxicity of these drugs. The investigated cells showed similar sensitivity to aclarubicin but different sensitivity to doxorubicin and mitoxantrone: mitoxantrone was the most cytotoxic drug in both cell lines. All three drugs triggered both apoptosis and necrosis but none of these processes was positively correlated with their cytotoxicity. Apoptosis was the prevalent form of cell kill by aclarubicin, while doxorubicin and mitoxantrone induced mainly the necrotic mode of cell death. The extent and the timing of apoptosis were strongly dependent on the cell line, the type of the drug and its dose, and were mediated by caspase-3 activation. A significant increase in caspase-3 activity and the percentage of apoptotic cells, oligonucleosomal DNA fragmentation, chromatin condensation and formation of apoptotic bodies was observed predominantly in B14 cells. NIH 3T3 cells showed lesser changes and a lack of DNA fragmentation. Aclarubicin was the fastest acting drug, inducing DNA fragmentation 12 h earlier than doxorubicin, and 24 h earlier than mitoxantrone. Caspase-3 inhibitor Ac-DEVD-CHO did not show any significant effect on drug cytotoxicity and DNA nucleosomal fragmentation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16215684     DOI: 10.1007/s10495-005-1540-9

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  20 in total

1.  Expanding the chemical diversity of CK2 inhibitors.

Authors:  Renaud Prudent; Virginie Moucadel; Miriam López-Ramos; Samia Aci; Beatrice Laudet; Liliane Mouawad; Caroline Barette; Jacques Einhorn; Cathy Einhorn; Jean-Noel Denis; Gilles Bisson; Frédéric Schmidt; Sylvaine Roy; Laurence Lafanechere; Jean-Claude Florent; Claude Cochet
Journal:  Mol Cell Biochem       Date:  2008-06-18       Impact factor: 3.396

2.  Generic Hockey-Stick Model for Estimating Benchmark Dose and Potency: Performance Relative to BMDS and Application to Anthraquinone.

Authors:  Kenneth T Bogen
Journal:  Dose Response       Date:  2010-10-21       Impact factor: 2.658

3.  Switch in Site of Inhibition: A Strategy for Structure-Based Discovery of Human Topoisomerase IIα Catalytic Inhibitors.

Authors:  Ashish T Baviskar; Suyog M Amrutkar; Neha Trivedi; Vikas Chaudhary; Anmada Nayak; Sankar K Guchhait; Uttam C Banerjee; Prasad V Bharatam; Chanakya N Kundu
Journal:  ACS Med Chem Lett       Date:  2015-02-23       Impact factor: 4.345

4.  Novel Anthraquinone Compounds Induce Cancer Cell Death through Paraptosis.

Authors:  Wei Tian; Junying Li; Zhengying Su; Fu Lan; Zhaoquan Li; Dandan Liang; Chunmiao Wang; Danrong Li; Huaxin Hou
Journal:  ACS Med Chem Lett       Date:  2019-03-25       Impact factor: 4.345

5.  Cytotoxic and antimigratory effects of Cratoxy formosum extract against HepG2 liver cancer cells.

Authors:  Benjaporn Buranrat; Nootchanat Mairuae; Watchara Kanchanarach
Journal:  Biomed Rep       Date:  2017-03-10

Review 6.  Leveraging self-assembled nanobiomaterials for improved cancer immunotherapy.

Authors:  Michael P Vincent; Justin O Navidzadeh; Sharan Bobbala; Evan A Scott
Journal:  Cancer Cell       Date:  2022-02-10       Impact factor: 31.743

Review 7.  Immunogenic cell death and DAMPs in cancer therapy.

Authors:  Dmitri V Krysko; Abhishek D Garg; Agnieszka Kaczmarek; Olga Krysko; Patrizia Agostinis; Peter Vandenabeele
Journal:  Nat Rev Cancer       Date:  2012-11-15       Impact factor: 60.716

Review 8.  Ubiquitination and deubiquitination emerge as players in idiopathic pulmonary fibrosis pathogenesis and treatment.

Authors:  Shuang Li; Jing Zhao; Dong Shang; Daniel J Kass; Yutong Zhao
Journal:  JCI Insight       Date:  2018-05-17

9.  Phenotypic drug profiling in droplet microfluidics for better targeting of drug-resistant tumors.

Authors:  S Sarkar; N Cohen; P Sabhachandani; T Konry
Journal:  Lab Chip       Date:  2015-12-07       Impact factor: 6.799

10.  Mitoxantrone impairs proteasome activity and prompts early energetic and proteomic changes in HL-1 cardiomyocytes at clinically relevant concentrations.

Authors:  Vera Marisa Costa; João Paulo Capela; Joana R Sousa; Rute P Eleutério; Patrícia R S Rodrigues; José Luís Dores-Sousa; Rui A Carvalho; Maria Lourdes Bastos; José Alberto Duarte; Fernando Remião; M Gabriela Almeida; Kurt J Varner; Félix Carvalho
Journal:  Arch Toxicol       Date:  2020-09-07       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.